Zusammenfassung
Antikoagulantien und Thrombozytenaggregationshemmer werden in steigendem Umfang bei Thrombosen, Embolien und arteriellen Gefäßkrankheiten mit unterschiedlichen therapeutischen Schwerpunkten eingesetzt. Die akute Antikoagulation mit Heparin und die nachfolgende Gabe oraler Vitamin-K-Antagonisten ist die Standardtherapie für akute Venenthrombosen und Lungenembolien. Daneben werden orale Antikoagulantien zur Prophylaxe kardiogener Hirnembolien bei atrialen Thromben und bei arteriosklerotisch bedingten Karotisstenosen angewendet. Niedermolekulare Heparine werden überwiegend zur Prophylaxe thromboembolischer Komplikationen bei immobilisierten Patienten, aber auch zunehmend für die Therapie tiefer Venenthrombosen bei ambulanten Patienten eingesetzt.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Albers G.W., Amarenco P. (2001): Combination therapy with Clopidogrel and aspirin. Can the CURE results be extrapolated to cerebrovascular patients? Stroke 32: 2948–2949.
Algra A., de Schryver E.L., van Gijn J., Kappelle L.J., Koudstaal P.J. (2001): Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. Cochrane Database Syst. Rev. 2001(4): CD 001342.
Antithrombotic Trialists’ Collaboration (2002): Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Brit. Med. J. 324: 71–86.
Bertrand M.E., Rupprecht H.-J., Urban P., Gershlick A.H. for the CLASSICS Investigators (2000): Double-blind study of the safety of Clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 102: 624–629.
Born G.V.R., Collins R. (1997): Aspirin versus Clopidogrel: the wrong question? Lancet 349: 806–807.
Bousser M.G., Eschwege E., Haguenau M., Lefauconnier J.M., Thibult N. et al. (1983): „AICLA“ controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 14: 5–14.
CAPRIE Steering Committee (1996): A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329–1339.
Cohen M., Demers C, Gurfinkel E.P., Turpie A.G., Fromell G.J., Goodman S. et al. for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group (1997): A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N. Engl. J. Med. 337: 447–452.
Diener H.C., Cunha L., Forbes C, Sivenius J., Smets P., Lowenthal A. (1996): European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci. 143:1–13.
Eikelboom J.W., Hirsh J., Weitz J.I., Johnston M., Yi Q., Yusuf S. (2003): Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 105: 1650–1655.
Gent M., Blakely J.A., Easton J.D., Ellis DJ., Hachinski V.C. et al. (1989): The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet I: 1215–1220.
Ginsberg J.,Greer I., Hirsh J. (2001): Use of antithrombotic agents during pregnancy. Chest 119: 122S–131S.
Gorelick P.B., Born G.V.R., d’Agostino R.B., Hanley D.E Jr., Moye L., Pepine C.J. (1999): Therapeutic benefit. Aspirin revisited in light of the introduction of Clopidogrel. Stroke 30:1716–1721.
Grau E., Tenias J.M., Real E., Medrano J., Ferrer R., Pastor E., Selfa S. (2001): Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism. Am. J. Hematol. 67: 10–14.
Gum P.A., Kottke-Marchant K., Poggio E.D., et al. (2001): Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am. J. Cardiol. 88: 230–235.
Hass W.K., Easton J.D., Adams H.P. Jr., Pryse-Phillips W., Molony B.A. et al. (1989): A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N. Engl. J. Med. 321: 501–507.
Hirsh J., Levine M.N. (1992): Low molecular weight heparin. Blood 79:1–17.
Jneid H., Bhatt D.L., Corti R., Badimon, J.J., Fuster V., Francis G.S. (2003): Aspirin and Clopidogrel in acute coronary syndromes. Therapeutic insights from the CURE study. Arch. Intern. Med. 163: 1145–1153.
Keng T. B. (2001): Heparin-induced thrombocytopenia and thrombosis syndrome: in vivo cross-reactivity with danaparoid and successful treatment with r-Hirudin. Br. J. Haematol. 114: 394–396.
Klimt C.R., Knatterud G.L., Stamler J., Meier P. (1986): Persantine-aspirin reinfarction study. Part II. Secondary coronary prevention with persantine and aspirin. J. Am. Coll. Cardiol. 7:251–269.
Kock H.-J., Schmit-Neuerburg K.P., Hanke J., Rudofsky G., Hirche H. (1995): Thromboprophylaxis with low-molecular-weight heparin in outpatients with plastercast immobilisation of the leg. Lancet 346: 459–461.
Koopman M.M.W., Prandoni P., Piovella R, Ockelford P.A., Brandjes D.P.M. et al. (1996): Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N. Engl. J. Med. 334: 682–687.
Leizorovicz A., Haugh M.C., Chapuis F.-R., Samama M.M., Boissel J.-R (1992): Low molecular weight heparin in prevention of perioperative thrombosis. Brit. Med. J. 305: 913–920.
Lensing A.W.A., Prins M.H., Davidson B.L., Hirsh J. (1995): Treatment of deep venous thrombosis with low-molecular-weight heparins: a meta-analysis. Arch. Intern. Med. 155: 601–607.
Leon M.B., Bairn D.S., Popma J.J., Gordon P.C., Cutlip D.E., Ho K.K.L. et al. (1998): A clinical trial comparing three antithrombotic-drug regimens after coronaryartery stenting. N. Engl. J. Med. 339: 1665–1671.
Levine M., Gent M., Hirsh J., Leclerc J., Anderson D. et al. (1996): A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N. Engl. J. Med. 334: 677–681.
Mehta S.R., Yusuf S., Peters R.J.G., Bertrand M.E., Lewis B.L., Katarajan M.K. et al. for the Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators (2001): Effects of pretreatement with Clopidogrel and aspirin followed by long-term thearpy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 358: 527–533.
Moussa L, Oetgen M., Roubin G., Colombo A., Wang X., Iyer S. et al. (1999): Effectiveness of Clopidogrel and aspirin versus ticlopidine and aspirin in preventing Stent thrombosis after coronary stent implantation. Circulation 99: 2364–2366.
The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001): Effects of Clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation. N. Engl. J. Med. 345: 494–502.
The Persantine-Aspirin Reinfarction Study Research Group (1980): Persantine and aspirin in coronary heart disease. Circulation 62: 449–461.
Van der Heijden J.F., Hutten B.A., Büller H.R., Prins M.H. (2002): Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism (Cochrane Revies). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software.
Walenga J.M. (2002): Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb. Res. 105: 401–405.
Wenzel E., Keller-Stanislawski B., Tiaden J.D., Mörsdorf S., Pindur G., Graul A., Seyfert U.T. (1999): Antithrombotische, blutstillende und antianämische Mittel. In: Müller-Oerlinghausen B., Lasek R., Düppenbecker H., Munter K.-H. (Hrsg.): Handbuch der unerwünschten Arzneimittelwirkungen. Urban & Fischer, München.
Zed P.J., Tisdale J.E., Borzak S. (1999): Low-molecular-weight heparins in the management of acute coronary syndromes. Arch. Intern. Med. 159: 1849–1857.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schwabe, U. (2004). Antikoagulantien und Thrombozytenaggregationshemmer. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2003. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18512-0_14
Download citation
DOI: https://doi.org/10.1007/978-3-642-18512-0_14
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-40188-9
Online ISBN: 978-3-642-18512-0
eBook Packages: Springer Book Archive